Please provide your email address to receive an email when new articles are posted on . Patients with severe degenerative mitral regurgitation saw sustained benefits with a novel transcatheter edge-to ...

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...

SAN FRANCISCO, CA—For patients with symptomatic degenerative mitral regurgitation (DMR) and a prohibitive surgical risk, transcatheter edge-to-edge repair (TEER) with either of two approved devices ...

Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL ...

"In surgery ... we would all be horrified," said one physician ...

SAN FRANCISCO -- The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results from ...

BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...

Your mitral valve is one of the four major valves in your heart. It helps blood flow through your heart and out to the rest of your body. When this valve isn’t working correctly, it puts stress on ...

Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare ...

UC San Francisco interventional cardiologists and interventional echocardiographers recently performed two novel minimally invasive cardiac procedures for the first time in the health system.

BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...